Small-cell lung cancer

[1]  R. Stahel,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Minna,et al.  Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo , 2004, Cancer Gene Therapy.

[3]  M. Sheikh,et al.  Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest , 2004, Oncogene.

[4]  Jeffrey D Bradley,et al.  Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. A. Robinson,et al.  Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. , 2004, Journal of the National Cancer Institute.

[6]  G. Fontanini,et al.  Expression and Mutational Status of c-kit in Small-Cell Lung Cancer , 2004, Clinical Cancer Research.

[7]  J. Minna,et al.  Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[8]  J. Minna,et al.  Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. , 2004, Cancer research.

[9]  E. Schmidt.  The role of c-myc in regulation of translation initiation , 2004, Oncogene.

[10]  A. Twijnstra,et al.  Asymptomatic Brain Metastases (BM) in Small Cell Lung Cancer (SCLC): MR-imaging is Useful at Initial Diagnosis , 2000, Journal of Neuro-Oncology.

[11]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[12]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Rigas,et al.  O-107 Adjuvant targeted therapy in unresectable lung cancer: The results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI) , 2003 .

[14]  F. Bray,et al.  Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. , 2003, The Lancet. Oncology.

[15]  D. Sanders.  Lambert‐Eaton Myasthenic Syndrome , 2003, Annals of the New York Academy of Sciences.

[16]  R. Hatlevoll,et al.  Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Giaccone,et al.  Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Kaye,et al.  RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer , 2002, Oncogene.

[19]  P. Jänne,et al.  Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America , 2002, Cancer.

[20]  N. Saijo,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[22]  J. Verbalis,et al.  Systemic diseases associated with disorders of water homeostasis. , 2002, Endocrinology and metabolism clinics of North America.

[23]  Y. Pekarsky,et al.  FHIT as Tumor Suppressor: Mechanisms and Therapeutic Opportunities , 2002, Cancer biology & therapy.

[24]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[25]  S. Khuder,et al.  Effect of smoking cessation on major histologic types of lung cancer. , 2001, Chest.

[26]  J. Lafitte,et al.  A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics , 2001, British Journal of Cancer.

[27]  J. Minna,et al.  Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells , 2001, Oncogene.

[28]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[29]  B. O'driscoll,et al.  Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy. , 2001, Respiratory medicine.

[30]  E. Lemarié,et al.  Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. , 2001, Journal of the National Cancer Institute.

[31]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[32]  M. Jordá,et al.  Small cell carcinoma versus other lung malignancies , 2000, Cancer.

[33]  Eric S. Lander,et al.  Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays , 2000, Nature Biotechnology.

[34]  V. Ninane,et al.  Prognostic factors for patients with small cell lung carcinoma , 2000, Cancer.

[35]  M. Motomura,et al.  Apheresis treatment in Lambert-Eaton myasthenic syndrome. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[36]  H. Dosaka-akita,et al.  A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer. , 2000, Antisense & nucleic acid drug development.

[37]  T. McCain,et al.  Increasing use of bronchoscopic needle aspiration to diagnose small cell lung cancer. , 2000, Mayo Clinic proceedings.

[38]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[39]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[40]  M. Suntharalingam,et al.  Comparison of three treatment options for single brain metastasis from lung cancer , 2000, International journal of cancer.

[41]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[42]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[44]  M. Rosenfeld,et al.  P/Q‐type voltage‐gated calcium channel antibodies in paraneoplastic disorders of the central nervous system , 1999, Muscle & nerve.

[45]  A. Paccagnella,et al.  Long term results of surgery and chemotherapy in small cell lung cancer. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[46]  R. Brezinschek,et al.  Mutation analysis of the PTEN/MMAC1 gene in lung cancer , 1998, Oncogene.

[47]  M. Fukuoka,et al.  Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. , 1998, British Journal of Cancer.

[48]  D. Sanders,et al.  Lambert‐Eaton Myasthenic Syndrome (LEMS): Clinical and Electrodiagnostic Features and Response to Therapy in 59 Patients , 1998, Annals of the New York Academy of Sciences.

[49]  J. Minna,et al.  Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types , 1998, Genes, chromosomes & cancer.

[50]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Ettinger,et al.  Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. , 1997, Journal of the National Cancer Institute.

[52]  D. Venzon,et al.  A prospective study of patients with lung cancer and hyponatremia of malignancy. , 1997, American journal of respiratory and critical care medicine.

[53]  D. Girling,et al.  Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial , 1997 .

[54]  R. Souhami,et al.  Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. , 1997, Journal of the National Cancer Institute.

[55]  R E Albright,et al.  Stereotactic radiosurgery for the treatment of brain metastases , 1997, Cancer.

[56]  R. Stephens,et al.  Long-term survival in small cell lung cancer: the case for a standard definition , 1996 .

[57]  M. Kane,et al.  Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. , 1996, Lung cancer.

[58]  D. Girling.  Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial , 1996, The Lancet.

[59]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[60]  S. Clarke,et al.  Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. , 1996, European journal of cancer.

[61]  John Calvin Reed,et al.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells , 1996, Molecular and cellular biology.

[62]  T. Flynn,et al.  Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer , 1995, Cancer.

[63]  S. Dahrouge,et al.  Oral Etoposide and Carboplatin: Effective Therapy for Elderly Patients with Small Cell Lung Cancer , 1995, American journal of clinical oncology.

[64]  P Chomy,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. , 1995, Journal of the National Cancer Institute.

[65]  D. London,et al.  ACTH precursors characterize the ectopic ACTH syndrome , 1994, Clinical endocrinology.

[66]  J P Pignon,et al.  Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.

[67]  P. Postmus,et al.  Long term survival of small cell lung cancer patients after chemotherapy. , 1993, British Journal of Cancer.

[68]  D. Venzon,et al.  Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. , 1993, Archives of internal medicine.

[69]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[70]  J P Pignon,et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.

[71]  R C Brownson,et al.  Gender and histologic type variations in smoking-related risk of lung cancer. , 1992, Epidemiology.

[72]  R. Slawson,et al.  Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer. , 1991, International journal of radiation oncology, biology, physics.

[73]  K. Suemasu,et al.  Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[74]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[75]  R. Holle,et al.  Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. , 1991, British Journal of Cancer.

[76]  C. Chalk,et al.  Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma , 1990, Neurology.

[77]  K. Kamoi,et al.  Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus. , 1990, The Journal of clinical endocrinology and metabolism.

[78]  J. Daube,et al.  3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. , 1989, The New England journal of medicine.

[79]  E. Sher,et al.  SPECIFICITY OF CALCIUM CHANNEL AUTOANTIBODIES IN LAMBERT-EATON MYASTHENIC SYNDROME , 1989, The Lancet.

[80]  V. Gebski,et al.  Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. , 1989, British Journal of Cancer.

[81]  D. Osoba,et al.  Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. , 1987, Annals of internal medicine.

[82]  J. Habener,et al.  Transient elevation of messenger RNA encoding gastrin-releasing peptide, a putative pulmonary growth factor in human fetal lung. , 1987, The Journal of clinical investigation.

[83]  J. Minna,et al.  Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer , 1987, Nature.

[84]  J. Battey,et al.  Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. , 1986, The Journal of clinical investigation.

[85]  H. Hansen,et al.  Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. , 1986, European journal of cancer & clinical oncology.

[86]  C. Chute,et al.  Presenting conditions of 1539 population‐based lung cancer patients by cell type and stage in new hampshire and vermont , 1985, Cancer.

[87]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[88]  J. Forrest,et al.  Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. , 1978, The New England journal of medicine.

[89]  W. Fox,et al.  Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. , 1973, Lancet.

[90]  C. Capen,et al.  Biosynthesis of vasopressin in vitro and ultrastructure of a bronchogenic carcinoma. Patient with the syndrome of inappropriate secretion of antidiuretic hormone. , 1972, The Journal of clinical investigation.

[91]  E. Lambert,et al.  QUANTAL COMPONENTS OF END‐PLATE POTENTIALS IN THE MYASTHENIC SYNDROME * , 1971, Annals of the New York Academy of Sciences.

[92]  J. Berg,et al.  Oat cell lung cancer , 1962, The American journal of nursing.

[93]  W. Barnard.  The nature of the “oat‐celled sarcoma” of the mediastinum , 1926 .